

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. §1.98(b))

Attorney Docket No.

00398/512002

Serial No.

09/966,871

Applicant

Alan S. Kopin et al.

Filing Date

September 28, 2001

Group

Not Assigned

IDS Filed

January 11, 2002

Customer No.

21559

02 JAN 11 PM 1:13

RECEIVED
TECH CENTER 1600/2900

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Applicable)
2	5,882,944	03/1999	Sadee			
2	5,879,896	03/1999	Hinuma et al.			
2	5,750,353	05/1999	Kopin et al.			
2	5,521,175	05/1996	Castro Pineiro et al.			

RECEIVED
MAY 08 2002

TECH CENTER 1600/2900

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
2	WO 96/30406	10/03/96	PCT			
2	WO 96/25432	08/22/96	PCT			
2	WO 96/11946	04/25/96	PCT			
2	WO 96/11691	04/25/96	PCT			
2	WO 96/11689	04/25/96	PCT			
2	WO 95/06117	03/02/95	PCT			
2	WO 95/00848	01/05/95	PCT			
2	WO 94/24149	10/27/94	PCT			
2	WO 94/03437	02/17/94	PCT			
2	WO 93/14074	07/22/93	PCT			
2	EP 0 678 577 A2	10/25/95	European Patent Office			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

2	Allen et al., "G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the α_{1p} -adrenergic receptor enhances mitogenesis and tumorigenicity" <i>Proc. Natl. Acad. Sci. USA</i> 88:11354-11358 (1991)
2	Barker et al., "Constitutively active 5-hydroxytryptamine _{2c} receptors reveal novel inverse agonist activity of receptor ligands" <i>J. Biol. Chem.</i> 269:11687-11690 (1994)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Attorney Docket No.	00398/512002
	Serial No.	09/966,871
	Applicant	Alan S. Kopin et al.
	Filing Date	September 28, 2001
	Group	Not Assigned
	IDS Filed	January 15, 2002
(37 C.F.R. §1.98(b))	Customer No.	21559

RECEIVED
MAY 08 2002
TECH CENTER 1600/2900

1	Beinbom et al., "A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists" <i>Nature</i> 362:348-350 (1993)
2	Black et al., "Inverse agonists exposed" <i>Nature</i> 374:214-215 (1995)
2	Blevins et al., "Characterization of cholecystokinin _A receptor agonist activity by a family of cholecystokinin _B receptor agonists" <i>J. Pharmacol. Exp. Ther.</i> 269:911-916 (1994)
2	Bond et al., "Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β_2 -adrenoceptor" <i>Nature</i> 374:272-276 (1995)
2	Chang et al., "A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from <i>Aspergillus Alliaceus</i> " <i>Science</i> 230:177-179 (1985)
2	Chen et al., "Molecular cloning and functional expression of a μ -opioid receptor from rat brain" <i>Molecular Pharmacology</i> 44:8-12 (1993)
2	Chen et al., "Physiological disposition and metabolism of L-365,260, a potent antagonist of brain cholecystokinin receptor, in laboratory animals" <i>Drug Metabolism and Disposition</i> 20:390-395 (1992)
2	Chu et al., "Effect of endogenous hypergastrinemia on gastrin receptor expressing human colon carcinoma transplanted to athymic rats" <i>Gastroenterology</i> 109:1415-1420 (1995)
2	Clapham, "Mutations in G protein-linked receptors: novel insights on disease" <i>Cell</i> 75:1237-1239 (1993)
2	Coughlin, "Expanding horizons for receptors coupled to G proteins: diversity and disease" <i>Current Opinion in Cell Biology</i> 6:191-197 (1994)
2	DeLean et al., "A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β -adrenergic receptor" <i>J. Biol. Chem.</i> 255:7108-7117 (1980)
2	Dethloff et al., "Cholecystokinin antagonists - a toxicologic perspective" <i>Drug Metabolism Reviews</i> 24:267-296 (1992)
2	Ding et al., "Cholecystokinin-B receptor ligands of the dipeptoid series act as agonists on rat stomach histidine decarboxylase" <i>Gastroenterology</i> 109:1181-1187 (1995)
2	Dourish et al., "Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors" <i>Science</i> 245:1509-1511 (1989)
2	Evans et al., "Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin" <i>Proc. Natl. Acad. Sci. USA</i> 83:4918-4922 (1986)
2	Guidobono et al., "Stress related changes in calcitonin gene-related peptide binding sites in the cat central nervous system" <i>Neuropeptides</i> 31:57-63 (1991)
	Harro et al., "CCK in animal and human research on anxiety" <i>Trends Pharmacol. Sci.</i> 14:244-249 (1993)


EXAMINER 	DATE CONSIDERED 5-25-04
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00398/512002
		Serial No.	09/966,871
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Alan S. Kopin et al.
		Filing Date	September 28, 2001
		Group	Not Assigned
		IDS Filed	January 11, 2002
		Customer No.	21559

(37 C.F.R. §1.98(b))

RECEIVED
MAY 08 2002
TECH CENTER 1600/2900

2	Hausdorff et al., "A mutation of the β_2 -adrenergic receptor impairs agonist activation of adenylyl cyclase without affecting high affinity agonist binding" <i>J. Biol. Chem.</i> 265:1388-1393 (1990)
2	Heinflink et al., "A constitutively active mutant thyrotropin-releasing hormone receptor is chronically down-regulated in pituitary cells: evidence using chlordiazepoxide as a negative antagonist" <i>Molecular Endocrinology</i> 9:1455-1460 (1995)
2	Henke et al., "3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A agonists that demonstrate oral activity as satiety agents" <i>J. Med. Chem.</i> 39:2655-2658 (1996)
2	Höcker et al., "PD 135158, a CCK _B /gastrin receptor agonists, stimulates rat pancreatic enzyme secretion as a CCK _A receptor agonist" <i>Eur. J. Pharmacol.</i> 242:105-108 (1993)
2	Högger et al., "Activating and inactivating mutations in N- and C-terminal i3 loop junctions of muscarinic acetylcholine Hm1 receptors" <i>J. Biol. Chem.</i> 270:7405-7410 (1995)
2	Horwell, "Development of CCK-B antagonists" <i>Neuropeptides</i> 19(Suppl.):57-64 (1991)
2	Horwell, "Peptoid approaches in the design of antagonists of substance P and cholecystokinin" <i>Eur. J. Med. Chem.</i> 30 Suppl. 537s-550s (1995)
2	Horwell et al., "Rationally designed 'dipeptoid' analogues of CCK. α -methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties" <i>J. Med. Chem.</i> 34:404-414 (1991)
2	Ishizuka et al., "The effect of gastrin on growth of human stomach cancer cells" <i>Ann. Surg.</i> 215:528-535 (1992)
2	Jackson, "Structure and function of G protein coupled receptors" <i>Pharmacol. Ther.</i> 50:425-442 (1991)
2	Kenakin, "On the definition of efficacy. Antagonists may possess negative efficacy" <i>Trends Pharmacol. Sci.</i> 15:408-409 (1994)
2	Kjelsberg et al., "Constitutive activation on the α_{1B} -adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation" <i>J. Biol. Chem.</i> 267:1430-1433 (1992)
2	Koop et al., "A new CCK-B/gastrin receptor antagonist acts as an agonist on the rat pancreas" <i>Digestion</i> 54:286-287 (1993)
2	Kopin et al., "The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands" <i>J. Biol. Chem.</i> 270:5019-5023 (1995)
2	Kopin et al., "Expression cloning and characterization of the canine parietal cell gastrin receptor" <i>Proc. Natl. Acad. Sci. USA</i> 89:3605-3609 (1992)
2	Kopp et al., "Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene" <i>N. Engl. J. Med.</i> 332:150-154 (1995)
2	Latronico et al., "A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty" <i>J. Clin. Endocrinol. Metab.</i> 80:2490-2494 (1995)

EXAMINER 	DATE CONSIDERED 5-25-04
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))	Attorney Docket No.	00398/512002
	Serial No.	09/966,871
	Applicant	Alan S. Kopin et al.
	Filing Date	September 28, 2001
	Group	Not Assigned
	IDS Filed	January 11, 2002
	Customer No.	21559

RECEIVED
MAY 08 2002
TECH CENTER 1800/2900

2	Lazareno et al., "Estimation of antagonist K_b from inhibition curves in functional experiments: alternatives to the Cheng-Prusoff equation" <i>Trends Pharmacol. Sci.</i> 14:237-239 (1993)
2	Lee et al., "The human brain cholecystokinin-B/Gastrin Receptor" <i>J. Biol. Chem.</i> 268:8164-8169 (1993)
2	Leff, "The two-state model of receptor activation" <i>Trends Pharmacol. Sci.</i> 14:303-307 (1993)
2	Lefkowitz, "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins" <i>Trends Pharmacol. Sci.</i> 14:303-304 (1993)
2	Lefkowitz, "Turned on to ill effect" <i>Nature</i> 365:603-607 (1993)
2	Lloyd et al., "Peripheral regulation of gastric acid secretion" in <i>Physiology of the Gastrointestinal Tract</i> 1185-1226, Raven Press, New York (1994)
2	Lotti et al., "A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand L-365,260" <i>Eur. J. Pharmacol.</i> 162:273-280 (1989)
2	Matus-Leibovitch et al., "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in <i>xenopus</i> oocytes and AtT20 cells" <i>J. Biol. Chem.</i> 270:1041-1047 (1995)
2	McPherson, "Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC" <i>J. Pharmacol. Meth.</i> 14:213-228 (1985)
2	Milligan et al., "Inverse agonism: pharmacological curiosity or potential therapeutic strategy?" <i>Trends Pharmacol. Sci.</i> 16:10-13 (1995)
2	Nishida et al., "Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methyl-phenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, <i>in Vitro</i> and <i>in Vivo</i> " <i>J. Pharmacol. Exp. Ther.</i> 269:725-731 (1994)
2	Nishida et al., "YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats" <i>J. Pharmacol. Exp. Ther.</i> 270:1256-1261 (1994)
2	Parker et al., "Truncation of the extended carboxyl-terminal domain increases the expression and regulatory activity of the Avian β -adrenergic receptor" <i>J. Biol. Chem.</i> 266:9987-9996 (1991)
2	Parma et al., "Constitutively active receptors as a disease-causing mechanism" <i>Molec. Cell Endocrinol.</i> 100:159-162 (1994)
2	Parma et al., "Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas" <i>Nature</i> 365:649-651 (1993)
2	Parma et al., "Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3', 5'-monophosphate and inositol phosphate- Ca^{2+} Cascades" <i>Molecular Endocrinology</i> 9:725-733 (1995)

EXAMINER	DATE CONSIDERED 5-25-04
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT AND TRADEMARK OFFICE

Attorney Docket No.

00398/512002

Serial No.

09/966,871

Applicant

Alan S. Kopin et al.

Filing Date

September 28, 2001

Group

Not Assigned

IDS Filed

January 11, 2002

Customer No.

21559

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. §1.98(b))

RECEIVED
MAY 08 2002
TECH CENTER 1600/2000

2	Paschke et al., "Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid" <i>J. Clin. Endocrinol. Metab.</i> 79:1785-1789 (1994)
2	Patchett et al., "Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue" <i>Proc. Natl. Acad. Sci. USA</i> 92:7001-7005 (1995)
2	Patel et al., "Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity <i>in Vitro</i> and high potency <i>in Vivo</i> " <i>Molecular Pharmacology</i> 46:943-948 (1994)
2	Pei et al., "A constitutively active mutant β_2 -adrenergic receptor is constitutively desensitized and phosphorylated" <i>Proc. Natl. Acad. Sci. USA</i> 91:2699-2702 (1994)
2	Perlman et al., "Non-peptide angiotensin agonist" <i>J. Biol. Chem.</i> 270:1493-1496 (1995)
2	Pfeiffer et al., "Muscarinic M2-receptors enhance polyphosphoinositol release in rat gastric mucosal cells" <i>FEBS Letters</i> 204:352-356 (1986)
2	Porcellini et al., "Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas" <i>Oncogene</i> 11:1089-1093 (1995)
2	Rao et al., "Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness" <i>Nature</i> 367:639-641 (1994)
2	Ren et al., "Constitutively active mutants of the α_2 -adrenergic receptor" <i>J. Biol. Chem.</i> 268:16483-16487 (1993)
2	Robbins et al., "Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function" <i>Cell</i> 72:827-834 (1993)
2	Robinson et al., "Constitutively active mutants of rhodopsin" <i>Neuron</i> 9:719-725 (1992)
2	Sakamoto et al., "Distinct subdomains of human endothelin receptors determine their selectivity to endothelin _A -selective antagonist and endothelin _B -selective agonists" <i>J. Biol. Chem.</i> 268:8547-8553 (1993)
2	Samama et al., "A mutation-induced activated state of the β_2 -adrenergic receptor" <i>J. Biol. Chem.</i> 268:4625-4635 (1993)
2	Samama et al., "Negative antagonists promote an inactive conformation of the β_2 -adrenergic receptor" <i>Mol. Pharmacol.</i> 45:390-394 (1994)
2	Schipani et al., "A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia" <i>Science</i> 268:98-100 (1995)
2	Shenker et al., "A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty" <i>Nature</i> 365:652-654 (1993)
2	Showell et al., "High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCK _B /gastrin receptor antagonists containing a cationic solubilizing group" <i>J. Med. Chem.</i> 37:719-721 (1994)

EXAMINER

DATE CONSIDERED

5-25-04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Attorney Docket No.	00398/512002
	Serial No.	09/966,871
	Applicant	Alan S. Kopin et al.
	Filing Date	September 28, 1991
	Group	Not Assigned
	IDS Filed	January 11, 2002
(37 C.F.R. §1.98(b))	Customer No.	21559

RECEIVED
MAY 08 2002
TECH CENTER 1600/2900

✓	Strader et al., "Structure and function of G protein-coupled receptors" <i>Annu. Rev. Biochem.</i> 63:101-132 (1994)
✓	Strader et al., "A single amino acid substitution in the β -adrenergic receptor promotes partial agonist activity from antagonists" <i>J. Biol. Chem.</i> 264:16470-16477 (1989)
✓	Strader et al., "The family of G-protein-coupled receptors" <i>FASEB J.</i> 9:745-754 (1995)
✓	Straub et al., "Expression cloning of a cDNA encoding the mouse pituitary thyrotropin-releasing hormone receptor" <i>Proc. Natl. Acad. Sci USA</i> 87:9514-9518 (1990)
✓	Sugg, "Non-peptide agonist ligands for CCK-A receptors" Abstract (1995)
✓	Sung et al., "Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa" <i>J. Biol. Chem.</i> 268:26645-26649 (1993)
✓	Sunthomthepvarakul et al., "Brief Report: Resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene" <i>N. Engl. J. Med.</i> 332:155-160 (1995)
✓	Surratt et al., " μ opiate receptor" <i>J. Biol. Chem.</i> 269:20548-20553 (1994)
✓	Tiberi et al., "High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype" <i>J. Biol. Chem.</i> 269:27925-27931 (1994)
✓	Tseng et al., "Carboxyl-terminal domains determine internalization and recycling characteristics of bombesin receptor chimeras" <i>J. Biol. Chem.</i> 270:18858-18864 (1995)
✓	Wang et al., "Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence" <i>Life Sciences</i> 54:339-350 (1994)
✓	Watson et al., "Receptor & ion channel nomenclature supplement" <i>Trends Pharmacol. Sci.</i> Supplement 16 (1995)
✓	Westphal, "Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists" <i>Molec. Pharmacol.</i> 46:937-942 (1994)
✓	Westphal, "Properties of constitutively active serotonin 2C receptors (G protein, inverse agonist)" <i>Dissertations Abstracts Intl.</i> , Vanderbilt Univ. 56:(05-B)2578 (1995)
✓	Wiertelak et al., "Cholecystokinin antianalgesia: safety cues abolish morphine analgesia" <i>Science</i> 256:830-833 (1992)
✓	Yokota et al., "Delineation of structural domains involved in the subtype specificity of tachykinin receptors through chimeric formation of substance P/substance K receptor" <i>EMBO J.</i> 11:3585-3591 (1992)
✓	Yano et al., "A sporadic case of male-limited precocious puberty has the same constitutively activating point mutation in luteinizing hormone/choriogonadotropin receptor gene a familial cases" <i>J. Clinical Endocrinology & Metabolism</i> 79:1818-1823 (1994)

EXAMINER	DATE CONSIDERED 5-28-04
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

Sheet 1 of 1

SUBSTITUTE FORM PTO-116 DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE				Attorney Docket No. 00398/512002		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))				Serial No.	09/966,871	
				Applicant	Alan S. Kopin et al.	
				Filing Date	September 28, 2001	
				Group	1645	
				IDS Filed	June 13, 2002	
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
<i>[Signature]</i>	6,255,059	07/03/01	Klein et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
EXAMINER <i>[Signature]</i>			DATE CONSIDERED <i>5-20-04</i>			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

RECEIVED
JUN 21 2002
TECH CENTER 1600/2900